Minerva Neurosciences is a biopharmaceutical company developing treatments for central nervous system diseases. Its lead product is roluperidone (MIN-101) for schizophrenia, submitted for FDA approval. Another candidate, MIN-301, targets Parkinsons disease and neurodegenerative disorders. The company has a global licensing agreement for roluperidone, excluding Asia. Minerva was incorporated in 2007 and is headquartered in Massachusetts.
| Indicator | Value |
|---|---|
| PER | 8.8 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | 97.7% |
| Net Debt/EBITDA | 100.0 |